Cargando…
Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained. However, poor surviva...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797863/ https://www.ncbi.nlm.nih.gov/pubmed/33447446 http://dx.doi.org/10.21037/jtd-19-3703 |
_version_ | 1783634949662834688 |
---|---|
author | Yokoyama, Shintaro Miyoshi, Hiroaki |
author_facet | Yokoyama, Shintaro Miyoshi, Hiroaki |
author_sort | Yokoyama, Shintaro |
collection | PubMed |
description | Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained. However, poor survival period has been reported in unresectable cases exhibiting extensive invasion or distant metastasis, as effective chemotherapeutic regimens are restrained. We previously assessed expression of programmed death ligand 1 (PD-L1) and programmed death 1 (PD-1) and discussed their prospective application in the immunotherapy of thymic epithelial tumors. After our publication, additional studies using reliable PD-L1 antibodies, which are currently administered to predict efficacy of PD-1/PD-L1 blockade therapy were performed and further characterized PD-L1 in thymoma. Herein, recent knowledge in relation to the significance of PD-L1 expression in thymoma is reviewed based on recent findings using qualified PD-L1 clones. Most studies coherently found high expression of PD-L1 on the cell membrane and cytoplasm of tumor epithelial cells in accordance with previous reports, which is a predictive marker for effectiveness of anti-PD-1/PD-L1 drugs, even when approved PD-L1 antibodies were employed. On the other hand, PD-L1 expression on tumor infiltrating immune cells remains to be sufficiently determined. High PD-L1 expression can be expected in cases with high grade histological subtypes, such as type B2/B3 thymomas, or those with advanced stages III or IV of the disease. Interestingly, the level of PD-L1 expression was found to be upregulated after chemotherapy compared with that before, which could be explained by immunogenic cell death. The prognostic impact of PD-L1 expression in thymoma might be found only when thymic carcinoma patients were excluded. Furthermore, it also could be identified when we analyzed thymomas completely resected, distinct from biopsy and incompletely resected cases. |
format | Online Article Text |
id | pubmed-7797863 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-77978632021-01-13 Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma Yokoyama, Shintaro Miyoshi, Hiroaki J Thorac Dis Review Article on Thymoma Thymoma is a relatively rare malignancy, which is categorized as thymic epithelial tumor but known as the most common pathology that is developed in the anterior mediastinum. Complete resection is recommended for localized tumors and usually favorable prognosis can be obtained. However, poor survival period has been reported in unresectable cases exhibiting extensive invasion or distant metastasis, as effective chemotherapeutic regimens are restrained. We previously assessed expression of programmed death ligand 1 (PD-L1) and programmed death 1 (PD-1) and discussed their prospective application in the immunotherapy of thymic epithelial tumors. After our publication, additional studies using reliable PD-L1 antibodies, which are currently administered to predict efficacy of PD-1/PD-L1 blockade therapy were performed and further characterized PD-L1 in thymoma. Herein, recent knowledge in relation to the significance of PD-L1 expression in thymoma is reviewed based on recent findings using qualified PD-L1 clones. Most studies coherently found high expression of PD-L1 on the cell membrane and cytoplasm of tumor epithelial cells in accordance with previous reports, which is a predictive marker for effectiveness of anti-PD-1/PD-L1 drugs, even when approved PD-L1 antibodies were employed. On the other hand, PD-L1 expression on tumor infiltrating immune cells remains to be sufficiently determined. High PD-L1 expression can be expected in cases with high grade histological subtypes, such as type B2/B3 thymomas, or those with advanced stages III or IV of the disease. Interestingly, the level of PD-L1 expression was found to be upregulated after chemotherapy compared with that before, which could be explained by immunogenic cell death. The prognostic impact of PD-L1 expression in thymoma might be found only when thymic carcinoma patients were excluded. Furthermore, it also could be identified when we analyzed thymomas completely resected, distinct from biopsy and incompletely resected cases. AME Publishing Company 2020-12 /pmc/articles/PMC7797863/ /pubmed/33447446 http://dx.doi.org/10.21037/jtd-19-3703 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Article on Thymoma Yokoyama, Shintaro Miyoshi, Hiroaki Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma |
title | Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma |
title_full | Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma |
title_fullStr | Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma |
title_full_unstemmed | Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma |
title_short | Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma |
title_sort | comparison of pd-l1 immunohistochemical assays and the significance of pd-l1 expression in thymoma |
topic | Review Article on Thymoma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797863/ https://www.ncbi.nlm.nih.gov/pubmed/33447446 http://dx.doi.org/10.21037/jtd-19-3703 |
work_keys_str_mv | AT yokoyamashintaro comparisonofpdl1immunohistochemicalassaysandthesignificanceofpdl1expressioninthymoma AT miyoshihiroaki comparisonofpdl1immunohistochemicalassaysandthesignificanceofpdl1expressioninthymoma |